Salesforce Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Benzinga
28 May

Salesforce, Inc. (NYSE:CRM) will release its first-quarter earnings results after the closing bell on Wednesday, May 28.

Analysts expect the San Francisco, California-based company to report quarterly earnings at $2.55 per share, up from $2.44 per share in the year-ago period. Salesforce projects to report quarterly revenue at $9.75 billion, compared to $9.13 billion a year earlier, according to data from Benzinga Pro.

On Tuesday, Salesforce officially agreed to acquire Informatica for approximately $8 billion in equity value, net of Salesforce's current investment in Informatica.

Salesforce shares gained 1.5% to close at $277.19 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • UBS analyst Karl Keirstead maintained a Neutral rating and cut the price target from $320 to $300 on May 27, 2025. This analyst has an accuracy rate of 76%.
  • BMO Capital analyst Keith Bachman maintained an Outperform rating and slashed the price target from $367 to $350 on May 27, 2025. This analyst has an accuracy rate of 82%.
  • Citigroup analyst Tyler Radke maintained a Neutral rating and cut the price target from $335 to $320 on May 23, 2025. This analyst has an accuracy rate of 70%.
  • Mizuho analyst Gregg Moskowitz maintained an Outperform rating and cut the price target from $425 to $380 on May 15, 2025. This analyst has an accuracy rate of 72%.
  • Piper Sandler analyst Brent Bracelin maintained an Overweight rating and lowered the price target from $400 to $315 on April 23, 2025. This analyst has an accuracy rate of 76%.

Considering buying CRM stock? Here’s what analysts think:

Read This Next:

  • Jim Cramer Says Rocket Is A ‘Very Fine’ Company, Recommends Buying This Health Care Stock

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10